A citation-based method for searching scientific literature

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Maha Hussain, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Przemyslaw Twardowski, Guilhem Roubaud, Mustafa Özgüroğlu, Jinyu Kang, Joseph Burgents, Christopher Gresty, Claire Corcoran, Carrie A Adelman, Johann de Bono. N Engl J Med 2020
Times Cited: 151



DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu, Gunther Boysen, Nuria Porta, Penny Flohr, Alexa Gillman, Ines Figueiredo, Claire Paulding, George Seed, Suneil Jain, Christy Ralph, Andrew Protheroe, Syed Hussain, Robert Jones, Tony Elliott, Ursula McGovern, Diletta Bianchini, Jane Goodall, Zafeiris Zafeiriou, Chris T Williamson, Roberta Ferraldeschi, Ruth Riisnaes, Bernardette Ebbs, Gemma Fowler, Desamparados Roda, Wei Yuan, Yi-Mi Wu, Xuhong Cao, Rachel Brough, Helen Pemberton, Roger A'Hern, Amanda Swain, Lakshmi P Kunju, Rosalind Eeles, Gerhardt Attard, Christopher J Lord, Alan Ashworth, Mark A Rubin, Karen E Knudsen, Felix Y Feng, Arul M Chinnaiyan, Emma Hall, Johann S de Bono. N Engl J Med 2015
Times Cited: 1326




List of shared articles



Times cited

Recent Development and Future Prospects of Molecular Targeted Therapy in Prostate Cancer.
Jinku Zhang, Jirui Sun, Sahar Bakht, Waseem Hassan. Curr Mol Pharmacol 2022
2

First international workshop of the ATM and cancer risk group (4-5 December 2019).
Fabienne Lesueur, Douglas F Easton, Anne-Laure Renault, Sean V Tavtigian, Jonine L Bernstein, Zsofia Kote-Jarai, Rosalind A Eeles, Dijana Plaseska-Karanfia, Lidia Feliubadaló, Banu Arun,[...]. Fam Cancer 2022
3

Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.
Cathleen Nientiedt, Jan Budczies, Volker Endris, Martina Kirchner, Constantin Schwab, Christina Jurcic, Rouven Behnisch, Shirin Hoveida, Philippa Lantwin, Adam Kaczorowski,[...]. Urol Oncol 2022
2

PARP mediated DNA damage response, genomic stability and immune responses.
Chunyan Zong, Tianyu Zhu, Jie He, Rui Huang, Renbing Jia, Jianfeng Shen. Int J Cancer 2022
0

Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology.
Shreya M Shah, Elena V Demidova, Randy W Lesh, Michael J Hall, Mary B Daly, Joshua E Meyer, Martin J Edelman, Sanjeevani Arora. Cancer Treat Rev 2022
0

Olaparib-Induced Senescence Is Bypassed through G2-M Checkpoint Override in Olaparib-Resistant Prostate Cancer.
Alan P Lombard, Cameron M Armstrong, Leandro S D'Abronzo, Shu Ning, Amy R Leslie, Masuda Sharifi, Wei Lou, Christopher P Evans, Marc Dall'Era, Hong-Wu Chen,[...]. Mol Cancer Ther 2022
0

Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).
Maha Hussain, Claire Corcoran, Caroline Sibilla, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Joaquin Mateo, David Olmos, Niven Mehra,[...]. Clin Cancer Res 2022
1

[DNA repair gene alterations testing in prostate cancer : A practical update by the prostate cancer committee of the french association of urology].
G Ploussard, J-B Beauval, R Mathieu, E Barret, L Brureau, G Créhange, C Dariane, G Fiard, M Gauthé, R Renard-Penna,[...]. Prog Urol 2022
0

PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence.
Michał Bieńkowski, Bartłomiej Tomasik, Marcin Braun, Jacek Jassem. Cancer Treat Rev 2022
0

PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What's Now, What's New, and What's Coming?
Andrea Marchetti, Matteo Rosellini, Giacomo Nuvola, Elisa Tassinari, Veronica Mollica, Alessandro Rizzo, Matteo Santoni, Alessia Cimadamore, Andrea Farolfi, Rodolfo Montironi,[...]. Cancers (Basel) 2022
0

Angiogenesis as Therapeutic Target in Metastatic Prostate Cancer - Narrowing the Gap Between Bench and Bedside.
Antonio Giovanni Solimando, Charis Kalogirou, Markus Krebs. Front Immunol 2022
1

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers.
Diego Teyssonneau, Antoine Thiery-Vuillemin, Charles Dariane, Eric Barret, Jean-Baptiste Beauval, Laurent Brureau, Gilles Créhange, Gaëlle Fiard, Gaëlle Fromont, Mathieu Gauthé,[...]. J Clin Med 2022
0

Targeting radioresistance and replication fork stability in prostate cancer.
Xiangyi Li, GuemHee Baek, Suzanne Carreira, Wei Yuan, Shihong Ma, Mia Hofstad, Sora Lee, Yunpeng Gao, Claudia Bertan, Maria de Los Dolores Fenor de la Maza,[...]. JCI Insight 2022
0

Rucaparib and olaparib for the treatment of prostate cancer: A clinician's guide to choice of therapy.
Sidney Veach Keisner. J Oncol Pharm Pract 2022
0

Germline testing and genetic counselling in prostate cancer.
Jessica Russo, Veda N Giri. Nat Rev Urol 2022
0

Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas.
Nathan D Seligson, Joy Tang, Dexter X Jin, Monica P Bennett, Julia A Elvin, Kiley Graim, John L Hays, Sherri Z Millis, Wayne O Miles, James L Chen. NPJ Precis Oncol 2022
0

Homologous Recombination Repair Gene Variants and Outcomes Among Patients With Prostate Cancer Treated With Poly (ADP-ribose) Polymerase Inhibitors.
Meghan J Price, Vishal Vashistha, David Winski, Michael J Kelley, Rhonda L Bitting, Bruce Montgomery. JCO Precis Oncol 2022
0

PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer.
Ronan Flippot, Anna Patrikidou, Mihaela Aldea, Emeline Colomba, Pernelle Lavaud, Laurence Albigès, Natacha Naoun, Pierre Blanchard, Mario Terlizzi, Camilo Garcia,[...]. Drugs 2022
0

Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients.
Bruna Dalmasso, Alberto Puccini, Fabio Catalano, Roberto Borea, Maria Laura Iaia, William Bruno, Giuseppe Fornarini, Stefania Sciallero, Sara Elena Rebuzzi, Paola Ghiorzo. Int J Mol Sci 2022
0

Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis.
Baijun Dong, Bin Yang, Wei Chen, Xinxing Du, Liancheng Fan, Xudong Yao, Wei Xue. Med Oncol 2022
0

Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
Rebeca Lozano, Elena Castro, Isabel M Aragón, Ylenia Cendón, Carlo Cattrini, Pedro P López-Casas, David Olmos. Br J Cancer 2021
24

Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
Antje Neeb, Nicolás Herranz, Sara Arce-Gallego, Susana Miranda, Lorenzo Buroni, Wei Yuan, Alejandro Athie, Teresa Casals, Juliet Carmichael, Daniel Nava Rodrigues,[...]. Eur Urol 2021
26

Re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024.
Johann de Bono, Maha Hussain, Jinyu Kang. Eur Urol 2021
0

Clinical implications of genomic alterations in metastatic prostate cancer.
Takayuki Sumiyoshi, Kim N Chi, Alexander W Wyatt. Prostate Cancer Prostatic Dis 2021
4

Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
Axel S Merseburger, Nick Waldron, Maria J Ribal, Axel Heidenreich, Sven Perner, Karim Fizazi, Cora N Sternberg, Joaquin Mateo, Manfred P Wirth, Elena Castro,[...]. Eur Urol 2021
9

Prostate cancer.
Richard J Rebello, Christoph Oing, Karen E Knudsen, Stacy Loeb, David C Johnson, Robert E Reiter, Silke Gillessen, Theodorus Van der Kwast, Robert G Bristow. Nat Rev Dis Primers 2021
47

NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.
Edward Schaeffer, Sandy Srinivas, Emmanuel S Antonarakis, Andrew J Armstrong, Justin E Bekelman, Heather Cheng, Anthony Victor D'Amico, Brian J Davis, Neil Desai, Tanya Dorff,[...]. J Natl Compr Canc Netw 2021
63

SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
A González Del Alba, M J Méndez-Vidal, S Vazquez, E Castro, M A Climent, E Gallardo, E Gonzalez-Billalabeitia, D Lorente, J P Maroto, J A Arranz. Clin Transl Oncol 2021
3

Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer.
David Gonzalez, Joaquin Mateo, Albrecht Stenzinger, Federico Rojo, Michelle Shiller, Alexander W Wyatt, Frédérique Penault-Llorca, Leonard G Gomella, Ros Eeles, Anders Bjartell. J Pathol Clin Res 2021
9

Olaparib in Metastatic Castration-Resistant Prostate Cancer. Reply.
Maha Hussain, Chintu Desai, Johann de Bono. N Engl J Med 2021
0

Olaparib for the treatment of metastatic prostate cancer.
Corinne Maurice Dror, Alexander W Wyatt, Kim N Chi. Future Oncol 2021
0

Treatment and Patient Selection for Patients with Metastatic Castration-resistant Prostate After Progression on Docetaxel and Abiraterone/Enzalutamide: When to Play Your CARD and When to Do Your PARP.
Andrew G Robinson, Jason P Izard, Francisco E Vera-Badillo. Eur Urol 2021
2

Identification of a DNA Repair Gene Signature and Establishment of a Prognostic Nomogram Predicting Biochemical-Recurrence-Free Survival of Prostate Cancer.
Gongwei Long, Wei Ouyang, Yucong Zhang, Guoliang Sun, Jiahua Gan, Zhiquan Hu, Heng Li. Front Mol Biosci 2021
2

Prostate cancer and PARP inhibitors: progress and challenges.
Diego Teyssonneau, Henri Margot, Mathilde Cabart, Mylène Anonnay, Paul Sargos, Nam-Son Vuong, Isabelle Soubeyran, Nicolas Sevenet, Guilhem Roubaud. J Hematol Oncol 2021
14

The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.
Michelle Shen, Shiqin Liu, Tanya Stoyanova. Am J Clin Exp Urol 2021
4

Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer.
Benjamin L Maughan, Emmanuel S Antonarakis. Expert Opin Pharmacother 2021
1

Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
Jacob E Berchuck, Zhenwei Zhang, Rebecca Silver, Lucia Kwak, Wanling Xie, Gwo-Shu Mary Lee, Matthew L Freedman, Adam S Kibel, Eliezer M Van Allen, Rana R McKay,[...]. Eur Urol 2021
5

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Elizabeth M Swisher, Tanya T Kwan, Amit M Oza, Anna V Tinker, Isabelle Ray-Coquard, Ana Oaknin, Robert L Coleman, Carol Aghajanian, Gottfried E Konecny, David M O'Malley,[...]. Nat Commun 2021
24


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy